T-knife Therapeutics Announces Upcoming Presentations at Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Presentations to cover preclinical data for lead TCR-T candidate, TK-8001, and the protocol design for a Phase 1/2 trial of TK-8001 to treat MAGE-A1 positive solid tumorsSAN FRANCISCO, Oct. 01, 2021 (GLOBE

Related Keywords

Delbruck ,Nordrhein Westfalen ,Germany ,Berlin ,Sylvia Wheeler ,Kostenloser Wertpapierhandel ,Camille Landis ,Society For Immunotherapy Of Cancer ,Therapeutics Inc ,Wheelhouse Communications ,Globe Newswire Therapeutics Inc ,Max Delbruck Center ,Annual Meeting ,Eugen Leo ,Chief Medical Officer ,Melanoma Associated Antigen Gene A ,Molecular Medicine ,Business Officer ,Chief Financial ,Knife ,Herapeutics ,Nnounces ,Pcoming ,Presentations ,Society ,Immunotherapy ,Dancer ,Itc ,6th ,Nnual ,Meeting ,